Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00659334
Other study ID # IRB00001127
Secondary ID 5R01NS034608OHSU
Status Terminated
Phase Phase 2
First received
Last updated
Start date August 2000
Est. completion date March 2010

Study information

Verified date November 2022
Source OHSU Knight Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Combidex (ferumoxtran-10) is an ultra-small iron oxide particle covered with a sugar coating. It has been evaluated as an MRI contrast agent for use in imaging well perfused organs such as the liver and spleen and for imaging lymph nodes. In this study, Combidex is being used to compare the standard imaging agent, Gadolinium, in imaging brain tumors and the area adjacent to the tumor location. Combidex may provide the ability to better see brain tumors and inflammatory lesions on magnetic resonance imaging (MRI) scans. Combidex may be useful in its ability to cross blood vessels into brain tumors, and because of its size and ability to get into the area next to brain tumors, could assist in the treatment of brain tumors with other drugs in the future.


Description:

Subjects are recruited as patients in one of the neurology, neurosurgery or neuro-oncology clinics at OHSU. There are four groups of the study: - Subjects receive the combidex infusion only. - Subjects receive Combidex and undergo a previously schedule neurosurgery. - Subjects undergo surgery only and provide a sample of their tumor tissue to be used in pathology studies of Combidex. - Subjects with MS or stroke are invited to participate in receiving Combidex to evaluate the effectiveness of enhancing the area of damage within the brain. Subjects are deemed eligible for the study and undergo a baseline MRI within 28 days of receiving Combidex. Subjects receiving Combidex are admitted for a half day into the Oregon Clinical & Translational Research Institute(OCTRI). Combidex is infused I.V. over 30 minutes. Subjects are monitored for side effects and are discharged within about 5 hours after the infusion, if no complications have been noted. Subjects return 24 hours after the infusion for a post infusion MRI scan and return again to one of the neurology clinics for one month follow-up. Subjects enrolled in group 2 undergo surgery 1-2 days after the Combidex infusion and also undergo a 24 post infusion MRI and return for one month follow-up. These subjects are also followed closely by the neurosurgical physician during the course of follow-up. Subjects enrolled in group 3 only undergo surgery and agree to have a piece of their tumor resection or biopsy donated for use in the study. Group 4 is the same as group 1, except the patient population includes multiple sclerosis and stroke instead of patients with brain tumors.


Recruitment information / eligibility

Status Terminated
Enrollment 116
Est. completion date March 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender All
Age group 5 Years to 75 Years
Eligibility Inclusion Criteria: - Brain tumor or CNS inflammatory lesion including stroke or MS - 5 yrs old or older - Able to undergo MRI without general anesthesia - Agree to be followed for 1 month following infusion of Combidex - Sign a written informed consent - If female and of child-bearing potential, be postmenopausal, sterile, or be on birth control for 1 month prior to study - Must have a pre-treatment MRI within 28 days before study Exclusion Criteria: - Clinically significant signs of uncal herniation - Allergy to study drug, Combidex - Hepatic insufficiency - Stage IV or V renal insufficiency - If female, pregnant or lactating - Require anesthesia for MRI scanning - Hemachromatosis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ferumoxtran-10 (Combidex)
2.6 mg/kg
Procedure:
Neurosurgery
neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.

Locations

Country Name City State
United States Oregon Health & Science University Portland Oregon

Sponsors (3)

Lead Sponsor Collaborator
OHSU Knight Cancer Institute National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Experience Optimal Imaging in Adult and Pediatric Brain Tumors to Establish Timing and Sequencing Parameters of Combidex. Signal intensity change in participants with Pre and 24 hours Post Combidex on T1, T2, T2* MRI sequences will be assessed (some patients undergo scans at 3 and 72 hours in order to assess radiographic changes at these time points). Combidex will be administered in dose 2.6 mg/kg in adults with high and low grade gliomas, metastases, meningiomas, and PNET; and in pediatric patients with astrocytomas grade i-iv, brain stem gliomas, ependymomas, CNS germ cell tumors, and PNET. 24 hours (some patients between 3 and 72 hours) after administration of Combidex
Secondary Assess the Cellular Uptake of Particles in Brain Tumor Patients by Comparing Imaging Results With Histology and Electron Microscopic Examination of Biopsy Tissue 2 years
Secondary Compare Combidex Imaging in Brain Tumor Patients, With Other CNS Inflammatory Lesions Such as Multiple Sclerosis and Stroke. 2 years
Secondary Compare Pre- and Post-op Gd Enhanced MRI Combidex Enhanced MR Imaging Done Pre-, Intra- and Post-operatively, to Assess the Degree of Resection and Residual Tumor. 2 years
See also
  Status Clinical Trial Phase
Completed NCT02810899 - Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Phase 4
Withdrawn NCT00977795 - A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors Phase 1/Phase 2
Recruiting NCT00787982 - Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors Phase 1/Phase 2
Withdrawn NCT00555984 - Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors N/A
Completed NCT00038441 - Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas Phase 1/Phase 2
Recruiting NCT03619694 - Role of MR Spectroscopy in Brain Tumors
Withdrawn NCT01236586 - RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Unknown status NCT02775136 - An Evaluation of a Non-invasive Brain Monitor N/A
Completed NCT01244737 - FLT-PET Imaging of Brain Tumors in Children Phase 2
Completed NCT00993057 - Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia Early Phase 1
Terminated NCT00769093 - Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy Phase 1
Completed NCT00392119 - MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors Phase 1
Completed NCT00062478 - Study of Karenitecin (BNP1350) in Patients With Brain Tumors Phase 2
Terminated NCT00038389 - Study of Vioxx and Radiation Therapy for Brainstem Glioma Phase 1
Recruiting NCT05049148 - Platelets Activation in Brain Neoplasms N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT04712721 - Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. Early Phase 1
Completed NCT02881957 - Hypovitaminosis D in Neurocritical Patients Phase 2/Phase 3
Terminated NCT01954576 - NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme N/A
Recruiting NCT05538130 - A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors Phase 1